Phloridzin Neuroprotective Potential in Alleviating Scopolamine-Induced Alzheimer's Disease in Male Wistar Rats

Main Article Content

Rabiya Ahsan, Mohd Muazzam Khan, Anuradha Mishra, Vijayshwari Mishra, Gazala Noor, Usama Ahmad, Farogh Ahsan


Introduction: The increasing prevalence of Alzheimer's disease (AD) has necessitated the search for effective therapeutic agents capable of mitigating its progression. Phloridzin, has been the subject of numerous studies highlighting its protective effects in various neurodegenerative disorders

Objectives: The main objective of this study was to evaluate the neuroprotective effect of Phloridzin against scopolamine-induced Alzheimer's disease in Wistar rats

Methods: Alzheimer's was induced by scopolamine in male Wistar rats. After 7 days of acclimatization, the rats were administered daily intraperitoneal treatment with scopolamine (0.7 mg/kg), and Phloridzin (10 mg/kg) was given orally for 13 days. The neuro-cognitive function of treated rats was evaluated by the Morris Water Maze test, along with assessments of locomotor activity, AChE activity, protein levels, antioxidant parameters, and brain histopathology (hippocampus). 

Results: Scopolamine treated rats have shown a significant (*P<0.05) increase in AChE levels as compared to the normal group. However, AChE levels significantly (*P<0.05) decreased after the treatment with Phloridzin and a similar result was found in the total protein. Scopolamine administered rats were observed to have and to have an enhanced MDA level compared to NC, which was significantly (*P<0.05) reversed in Phloridzin-treated rats, indicating reduced lipid peroxidation. Reduced glutathione levels and glutathione peroxidase were significantly (*P<0.05) decreased, and SOD and catalase were significantly (*P<0.05) reduced in scopolamine-treated rats. These levels significantly increased after Phloridzin treatment.

Conclusions: Phloridzin improved the neuroprotective effect against Alzheimer's disease and enhanced neuronal signaling pathways, specifically cholinergic pathways. This drug has shown potent efficacy and therapeutic potential against scopolamine-treated rats in Alzheimer's disease

Article Details